Remote Strategic ALS Launch Lead – Rare Neurology

Otsuka America Pharmaceutical Inc.; Nashville (TN); Remote; USD 158,000 - 252,000; Full time

Benefits offered by this job

Medical, dental, vision

401(k) match

Paid holidays

Tuition reimbursement

Student loan assistance

Job summary

Otsuka America Pharmaceutical Inc. is seeking a Strategic Account Liaison to support the launch and growth of its Rare Neurology Franchise.

This field-based role communicates complex clinical data, screening and treatment pathways, market access policies, and patient support information to ALS Centers of Excellence, healthcare providers, and key non-clinical stakeholders to advance patient care. Initially focused on launching FUS-ALS, the role will evolve with the portfolio.

Qualifications

• Understanding complex disease states and communicating clinical data clearly.
• Educate on disease state awareness, screening, diagnostic pathways, and urgency.
• Build relationships with HCPs and KOLs as credible resources.
• Explain access and patient support programs to support prescribing.

Responsibilities

• Educate on disease state awareness and screening pathways.
• Develop and maintain relationships with ALS Centers of Excellence and KOLs.
• Articulate access and patient support programs to enable therapy.
• Participate in conferences and scientific meetings to educate on rare neurology.

Skills

Clinical acumen

Education on disease state

HCP relationship building

Strategic account planning

Market access

Conference participation

Cross-functional collaboration

Training & compliance

Education

Bachelor’s Degree

Advanced clinical degrees prioritized

Job description

Otsuka America Pharmaceutical Inc. is seeking a Strategic Account Liaison to support the launch and growth of its Rare Neurology Franchise.

This field-based role communicates complex clinical data, screening and treatment pathways, market access policies, and patient support information to ALS Centers of Excellence, healthcare providers, and key non-clinical stakeholders to advance patient care. Initially focused on launching FUS-ALS, the role will evolve with the portfolio.